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Background: Single high-sensitivity troponin T (hs-TnT) measurement
is predictive of cardiac events in adults with congenital heart disease
(ACHD). We aimed to study the prognostic value of serial hs-TnT
measurements in stable patients with ACHD.
Methods: In total, 602 consecutive patients with ACHD were enrolled
in this prospective study (2011-2013). Blood sampling was performed
at enrollment and thereafter yearly during scheduled visits, up to 4
years. Hs-TnT, N-terminal pro B-type natriuretic peptide (NT-proBNP),
and estimated glomerular filtration rate (eGFR) were measured. The
composite primary endpoint was defined as all-cause mortality, heart
failure, arrhythmia, hospitalization, cardiac (re)interventions, or
thromboembolic events. The relationship between changes in serial hs-
TnT and the primary endpoint was studied by joint models with
adjustment for repeated NT-proBNP and eGFR.
Results: In 601 patients (median age, 33 [interquartile range, 25-41]
years, 42% women, 90% NYHA I), at least 1 hs-TnT measurement wasReceived for publication September 19, 2019. Accepted December 4, 2019.
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Contexte : Le dosage unique de la troponine T hypersensible (hs-TnT)
est predictif d’evenements cardiaques chez les adultes atteints de
cardiopathie congenitale. Notre objectif etait d’etudier la valeur pro-
nostique du dosage seriel de la hs-TnT chez des patients adultes
atteints de cardiopathie congenitale qui presentaient un etat stable.
Methodologie : Au total, 602 patients adultes atteints de cardiopathie
congenitale ont ete inscrits consecutivement à cette etude prospective
(2011-2013). Les prelèvements sanguins ont ete effectues au
moment de l’inscription et chaque annee par la suite au cours des
visites prevues, jusqu’à la quatrième annee. La hs-TnT, le propeptide
natriuretique de type B N-terminal (NT-proBNP) et le taux de filtration
glomerulaire estime (TFGe) ont ete mesures. Le paramètre
d’evaluation principal regroupait les decès toutes causes confondues,
l’insuffisance cardiaque, l’arythmie cardiaque, les hospitalisations, les
(re)interventions cardiaques et les evenements thromboemboliques.
La relation entre les variations des taux seriels de hs-TnT et leAdults with congenital heart disease (ACHD) have a lifelong
burden of morbidity and mortality,1 and therefore they
require attentive follow-up over the course of their lives. The
recommended frequency and intensity of follow-up are related
to the disease complexity;2 however, follow-up strategies are
mostly based on observational studies or expert opinion. Both
the need for life-long monitoring and the increased prevalence
of patients with ACHD3 have resulted in an increased health
care utilization.4 To be able to maintain an adequate and
sustainable management of patients with ACHD,noninvasive, objective, and accurate methods to monitor
patients are needed. Easily accessible blood biomarkers may be
useful in this respect.
Over the past few years, several prognostic blood biomarkers
in the ACHD population have been identified, among which
N-terminal pro B-type natriuretic peptide (NT-proBNP) thus
far reveals as most relevant.5-7 We recently demonstrated the
relevance of serial NT-proBNP measurements for risk stratifi-
cation in patients with ACHD.8 NT-proBNP is secreted by
cardiomyocytes in response to myocyte stretch and stimulated
by increased wall stress.9 However, deterioration of cardiac
function in ACHD may include more pathophysiologic path-
ways. High-sensitivity troponin T (hs-TnT), primarily known
for its diagnostic ability in acute coronary syndrome,10 is also
associated with ventricular dysfunction11,12 and with cardio-
vascular events in patients with ACHD.5 Secretion of troponin
T in chronic heart failure (HF) can be explained by various
postulated mechanisms including myocardial and sub-
endocardial ischemia, inflammation, and myocardialll rights reserved.
performed; a mean of 4.3 hs-TnT measurements per patient were
collected. After a median follow-up of 5.8 [interquartile range, 5.3-6.3]
years, 229 (38.1%) patients reached the primary endpoint. On
average, hs-TnT levels increased over time, and more in patients who
reached the primary endpoint (P < 0.001). A 2-fold higher hs-TnT was
associated with the primary endpoint (unadjusted hazard ratio, 1.62;
95% confidence interval, 1.44-1.82; P < 0.001). The association
remained after adjustment for repeated eGFR but not when adjusted
for repeated NT-proBNP; repeated NT-proBNP remained associated
with the primary endpoint.
Conclusion: In stable patients with ACHD, hs-TnT levels increased
before the occurrence of an event and repeated hs-TnT was associated
with the risk of adverse cardiac events. However, repeated hs-TnT was
not superior to repeated NT-proBNP.
paramètre d’evaluation principal a ete etudiee à l’aide de modèles
conjoints corriges pour tenir compte de la mesure repetee du taux de
NT-proBNP et du TFGe.
Resultats : Chez 601 patients (âge median : 33 ans [intervalle inter-
quartile : 25-41 ans], 42 % de sexe feminin, 90 % presentant une
maladie de classe I de la NYHA), au moins un dosage de la hs-TnT a
ete effectue; les investigateurs ont effectue, en moyenne, 4,3 dosages
de la hs-TnT par patient. Au terme d’un suivi median de 5,8 ans
[intervalle interquartile : 5,3-6,3 ans], le paramètre d’evaluation prin-
cipal a ete atteint chez 229 (38,1 %) patients. En moyenne, les taux de
hs-TnT ont augmente au fil du temps, et davantage dans le cas des
patients chez qui le paramètre d’evaluation principal a ete atteint (p <
0,001). Un taux de hs-TnT deux fois plus eleve etait associe au para-
mètre d’evaluation principal (rapport des risques instantanes non
corrige : 1,62; intervalle de confiance à 95 % : de 1,44 à 1,82; p <
0,001). L’association a persiste après la correction visant à tenir
compte de la mesure repetee du TFGe, mais pas après la correction
visant à tenir compte du dosage repete de la NT-proBNP; le dosage
repete de la NT-proBNP est demeure associe au paramètre
d’evaluation principal.
Conclusion : Chez des patients adultes atteints de cardiopathie con-
genitale qui presentaient un etat stable, les taux de hs-TnT ont
augmente avant la survenue d’un evenement, et le dosage repete de
la hs-TnT a ete associe au risque d’evenements cardiaques
indesirables. Toutefois, le dosage repete de la hs-TnT ne s’est pas
avere superieur au dosage repete de la NT-proBNP.
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Volume - 2020apoptosis.13 In chronic HF, the relative change in hs-TnT be-
tween 2 measurements has been associated with adverse clinical
outcomes.14 Serial hs-TnT measurements may as well be pre-
dictive of cardiac events in the ACHD population.
We assessed the temporal evolution of hs-TnT in stable
patients with ACHD over a 4-year period and studied the
relation between these longitudinal patterns and the risk of
any major adverse cardiac event: all-cause mortality, HF,
arrhythmia, hospitalization, cardiac (re)intervention, or
thromboembolic event.Methods
Study design and population
This prospective observational cohort study includes a total
of 602 consecutive patients with moderate-to-complex
ACHD, who routinely visited the outpatient clinic of the
Erasmus MC, a tertiary referral center, between April 2011
and April 2013. We excluded patients aged <18 years, those
with mild ACHD (isolated atrial or ventricular septal defect),
patients with an impaired renal function (defined as creatinine
>200 mmol/L), and pregnant women. The study protocol was
approved by the Erasmus MC medical ethics committee, and
all research subjects provided written informed consent. The
study was performed according to the principles outlined in
the declaration of Helsinki.
Patient treatment was according to the discretion of the
treating physician, based on current guidelines.2,15 At base-
line, patients underwent physical examination by a cardiolo-
gist, 12-lead electrocardiography, echocardiography, and
venous blood sampling. Patients returned for yearly follow-up
visits during the first 4 subsequent years after study inclusion,in which they received a complete cardiac assessment and
venous blood draw. Other aspects of the study protocol have
been described previously.5,16
Repeated blood sampling and hs-TnT measurements
Venous blood sampling was performed at baseline and all
repeated study visits. Blood samples were processed <2 hours
after collection and stored at 80C until batch analysis.
NT-proBNP was directly measured in fresh serum samples at
the clinical chemistry laboratory, using a commercial elec-
trochemiluminescence immunoassay (Roche Diagnostics,
Rotkreuz, Switzerland). Hs-TnT measurements were obtained
in 2 batches at the clinical chemistry laboratory of our center.
A total of 2574 serum measurements were collected, corre-
sponding to a mean of 4.3 measurements per patient. The first
batch analysis of 589 (baseline) samples was performed in
201512 and the next batch of 1985 (follow-up) samples in
2018. All hs-TnT measurements were performed with a
commercial electrochemiluminescence immunoassay (Roche
Diagnostics). The limit of detection was 5 ng/L and the limit
of blank was <3 ng/L. For analytical purposes, hs-TnT levels
below <3 ng/L were substituted with a level equal to 1.5 ng/
L. Hs-TnT level >14 ng/L was considered elevated. The
upper limit of normal for NT-proBNP was 14 pmol/L.
Samples had not undergone a prior freeze-thaw cycle. Analysts
were blinded to patients’ characteristics and endpoints.
Definition and assessment of endpoints
The primary study endpoint was a composite of all-cause
mortality, incident HF (HF requiring initiation or change
in HF medication, or requiring hospitalization), hospitaliza-
tion for cardiac reasons (eg, endocarditis), arrhythmia
Table 1. Baseline patients’ characteristics for all patients and according to the 1-year change in hs-TnT level
All patients with ACHD
Change in hs-TnT between baseline and 1-y measurement*
P-valueDecrease Stable (undetectable) Increase
No. of patients 601 132 100 326
Clinical characteristics
Age, y 32.5 [24.7-41.2] 32.5 [24.1-40.4] 25.8 [21.4-33.1] 34.8 [27.2-44.8] < 0.001
Sex: women, n (%) 253 (42) 94 (71) 26 (26) 205 (63) < 0.001
Surgical repair, n (%) 540 (90) 118 (89) 90 (90) 296 (91) 0.893
Age at initial surgical repair, y 3.7 [0.8-11.9] 3.1 [0.5-11.0] 1.9 [0.4-6.3] 5.5 [1.2-14.9] < 0.001
Cardiac medication use, n (%)y 212 (35) 50 (38) 18 (18) 134 (41) < 0.001
Body mass index, kg/m2 24.7  4.4 24.5  4.6 24.3  4.3 25.2  4.3 0.109
Heart rate, beats/min 74  13 73  14 74  13 74  13 0.586
Systolic blood pressure, mm Hg 126  16 127  17 124  16 127  16 0.296
O2 saturation<90%, n (%) 17 (3) 5 (4) 1 (1) 9 (3) 0.446
NYHA class II/III, n (%) 61 (10) 14 (11) 3 (3) 38 (12) 0.038
Congenital diagnosis, n (%)
Tetralogy of Fallot 179 (30) 33 (25) 27 (27) 101 (31) 0.398
Aortic stenosis 138 (23) 28 (21) 20 (20) 86 (26) 0.294
Aortic coarctation 112 (19) 26 (20) 27 (27) 51 (15) 0.036
TGA-mustard operation 65 (11) 14 (11) 6 (6) 38 (12) 0.268
TGA-arterial switch operation 24 (4) 6 (5) 10 (10) 5 (2) < 0.001
Congenitally corrected TGA 20 (3) 8 (6) 1 (1) 11 (3) 0.116
Fontan circulation 36 (6) 7 (5) 8 (8) 20 (6) 0.694
Functionally univentricular heart 7 (1) 2 (1) 0 (0) 5 (2) 0.461
PAH 9 (1) 2 (1) 1 (1) 4 (1) 0.939
REV/Rastelli 11 (2) 6 (5) 0 (0) 5 (2) 0.032
Electrocardiography
Sinus rhythm, n (%) 520 (87) 108 (82) 94 (94) 282 (87) 0.025
QRS duration, ms 112 [100-137] 118 [105-137] 102 [92-114] 114 [101-145] < 0.001
Echocardiography
Left atrial volume, mL/m2z 21 [15-29] 22 [15-36] 19 [15-23] 21 [17-30] 0.007
LV end-diastolic volume, mL/m2z 64  19 68  20 60  16 63  19 0.017
LV ejection fraction, %z 56  8 55  9 57  6 56  8 0.077
RV end-diastolic annulus
dimension, mm
42  8 43  9 39  7 43  8 < 0.001
RV fractional area change, % 38  11 38  12 42  10 37  11 0.031
Systemic ventricular function, n (%) 0.067
Normal 303 (50) 60 (46) 62 (62) 157 (48)
Mildly impaired 211 (35) 48 (36) 32 (32) 117 (36)
Moderately impaired 69 (12) 17 (13) 5 (5) 42 (13)
Severely impaired 18 (3) 7 (5) 1 (1) 10 (3)
Laboratory results
eGFR, mL/min/1.73 m2 90 [82-90] 90 [83-90] 90 [85-90] 90 [81-90] 0.125
NT-proBNP, pmol/L 15.2 [6.8-33.3] 17.4 [8.3-43.1] 10.7 [6.1-19.6] 16.4 [6.9-36.7] 0.001
Hs-TnT, ng/L 4.3 [1.5-7.2] 7.7 [5.6-11.79] 1.50 [1.5-1.5] 4.4 [1.5-6.5] < 0.001
ACHD, adults with congenital heart disease; eGFR, estimated glomerular filtration rate; hs-TnT, high-sensitivity troponin T; LV, left ventricular; NT-proBNP,
N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; REV, Reparation à l’Etage Ventriculaire;
RV, right ventricular; TGA, transposition of the great arteries.
* Includes only patients with hs-TnT measurement at both baseline and 1 year.
yBeta-blocker (n ¼ 90), ACE inhibitor (n ¼ 89), diuretic (n ¼ 71), antiarrhythmic (n ¼ 53), angiotensin receptor blocker (n ¼ 36).
z Left-sided volumes were not measured in patients with a systemic right ventricle, univentricular heart, PAH, or a poor acoustic window.
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Serial Troponin T in ACHD(symptomatic and recorded, or requiring treatment), throm-
boembolic events (ischemic cerebrovascular accident, pulmo-
nary embolism, or myocardial infarction), or cardiac (re)
interventions (surgical or percutaneous). The secondary study
endpoint was composed of all-cause mortality or incident HF.
All endpoint events were adjudicated by 2 investigators
(L.W.G and J.W.R.H) without knowledge of any biomarker
level. Patients who did not reach one of the endpoints were
censored after January 1, 2018.
Statistical analysis
Continuous data are presented as mean  standard devi-
ation for normal distributed variables; otherwise the median
and interquartile range (IQR) is presented. Normality of
continuous variables was examined by visual inspection ofhistograms and Q-Q plots. Hs-TnT, estimated glomerular
filtration rate (eGFR), and NT-proBNP distributions were
skewed and 2log-transformed for further analyses. Cox pro-
portional hazard regression was used to investigate the asso-
ciation between baseline hs-TnT and study endpoints. We
presented crude hazard ratios (HRs) and HRs adjusted for a
range of baseline characteristics including age, sex, congenital
diagnosis (aortic stenosis, aortic coarctation, or arterial switch
operation vs tetralogy of Fallot (ToF), Rastelli, systemic RV,
univentricular heart, or pulmonary arterial hypertension),
NYHA class (NYHA I vs NYHA II/III), any cardiac medi-
cation use (angiotensin-converting-enzyme inhibitors, angio-
tensin II receptor blockers, beta-blockers, diuretics, calcium
blockers, or antiarrhythmic drugs), loss of sinus rhythm, sys-
temic ventricular function (continuous as 0-3), eGFR, and
NT-proBNP.
Table 2. Separate event components of the primary endpoint
Endpoint event N (%)
Death 25 (4.2)
Heart failure 59 (9.9)
Arrhythmia 127 (21.3)
Hospitalization 181 (30.4)
Cardiac (re)intervention 138 (23.2)
Thromboembolic event 29 (4.9)
Patients were followed until the occurrence of the event of interest and
were not censored at the time of another event type.
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temporal evolution of hs-TnT.17 Only measurements that
were taken before the occurrence of the study endpoints were
used. Joint modelling (combining linear mixed effect models
with Cox regression models) was applied to assess the asso-
ciation between individual hs-TnT trajectories and occurrence
of study endpoints.18 We report unadjusted HRs as well as
HRs adjusted for baseline characteristics and for repeatedly
measured NT-proBNP and eGFR.19 Furthermore, the abso-
lute change in hs-TnT during the first year was calculated
(Dyear 1-year 0), and the Kaplan-Meier method was used to
analyse survival according to subgroups based on this change.
A subanalysis was performed based on normal vs elevated
baseline NT-proBNP levels and also for 3 major diagnosis
groups: aortic coarctation, aortic stenosis, and ToF.
Covariates were >99% complete, and missing data were
therefore handled by imputation of the mean. SPSS version
24 and R statistical software version 3.5.1 (packages Survival,
nlme, JMbayes) were used for the analyses. All statistical tests
were 2-tailed, and P-values < 0.05 were considered statisti-
cally significant.Results
Baseline characteristics and study endpoints
At least 1 hs-TnT measurement was available in 601
(99.8%) patients, with a median age of 32.5 (IQR, 24.7-41.2)
years, 253 (42%) women, and 90% NYHA class I (Table 1).
In 47 (8%) patients, hs-TnT was elevated at baseline. In 196
(33%) patients, the baseline hs-TnT level was below the limit
of blank (<3.0 ng/L), and patients in whom hs-TnT levels
remained undetectable at 1 year (n ¼ 100) were on average
younger, less often NYHA II/III, more often in sinus rhythm,
and had a shorter QRS duration. Moreover, volumes of the
left atrium and end diastolic left ventricle were lower and the
right ventricular fractional area change was higher. Follow-upTable 3. Associations between baseline hs-TnT levels and endpoints
Primary endpo
HR (95% CI)
Hs-TnT (unadjusted) 1.38 (1.25-1.52)
Adjusted for baseline characteristics* 1.12 (0.99-1.27)
Adjusted for baseline NT-proBNP 1.10 (0.99-1.22)
Adjusted for baseline characteristics*
and baseline NT-proBNP
0.99 (0.87-1.12)
HRs are expressed per 2-fold higher hs-TnT level.
CI, confidence interval; HR, hazard ratio; hs-TnT, high-sensitivity troponin T;
* Age, sex, congenital diagnosis, NYHA class, any cardiac medication, loss of sindata were available in 596 (99.1%) patients. During a median
of 5.8 (IQR, 5.3-6.3) years of follow-up, respectively, 229
(38.1%) and 69 (11.6%) unique patients reached the primary
and secondary endpoint. Separate components of the
endpoint events are shown in Table 2, and median baseline
hs-TnT for achievement of each separate event of interest is
given in Supplemental Table S1. The occurrence of the pri-
mary endpoint was associated with an older age, cardiac
medication use, higher NYHA class, loss of sinus rhythm,
worse systemic ventricular function, and higher median
baseline hs-TnT (5.7 [IQR, 3.3-9.3] vs 3.8 [IQR, 1.5-6.1 ng/
mL]) (Supplemental Table S2).
Baseline hs-TnT was significantly associated with the pri-
mary and secondary endpoint. After adjustment for baseline
characteristics, hs-TnT remained significantly associated with
the secondary endpoint. The association between hs-TnT and
the study endpoints was no longer statistically significant after
adjustment for NT-proBNP (Table 3).Evolution of hs-TnT over time and its prognostic value
After omitting measurements that were taken after the
occurrence of the study endpoints, 2123 and 2460 hs-TnT
measurements were available for analysis concerning the pri-
mary and secondary endpoint, respectively. During the entire
follow-up period, hs-TnT was on average systematically
higher in patients who reached the primary endpoint than
those who remained endpoint-free (Fig. 1). Hs-TnT tended to
increase during follow-up both in patients with and without
the primary endpoint, though a higher increase was observed
in patients who reached the primary endpoint. Regarding the
secondary endpoint, hs-TnT levels increased during follow-
up, but the increase did not differ between patients with
and without the endpoint (Fig. 2).
Based on higher HRs obtained from joint models, repeated
hs-TnT was more strongly associated with the study end-
points compared with a single baseline hs-TnT measurement
(Table 4). The associations between repeated hs-TnT and the
study endpoints remained significant after adjustment for
baseline NT-proBNP and baseline characteristics separately,
but not when these data were combined. In a bimarker model,
repeated NT-proBNP, not repeated hs-TnT, was associated
with the study endpoints (Table 4).
A stratified analysis based on patients with normal or
elevated baseline NT-proBNP showed the absence of prog-
nostic value for a baseline hs-TnT in patients with normal
NT-proBNP, while repeated hs-TnT was associated with the
primary endpoint (Supplemental Fig. S2). However, in bothint Secondary endpoint
P-value HR (95% CI) P-value
< 0.001 1.92 (1.65-2.24) < 0.001
0.061 1.51 (1.22-1.86) < 0.001
0.084 1.21 (1.00-1.48) 0.050
0.842 1.23 (0.97-1.56) 0.091
NT-proBNP, N-terminal pro B-type natriuretic peptide.
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Figure 1. Average evolution of hs-TnT in patients with and without the primary endpoint. Measurements taken after the endpoint were discarded.
Time point zero is denoted as the time of study inclusion (A) or as the time when the event took place (B). hs-TnT, high-sensitivity troponin T; MACE,
major adverse cardiac event.
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Serial Troponin T in ACHDstrata, repeated hs-TnT was no longer associated when
adjusted for repeated NT-proBNP.
Hs-TnT yielded a stronger association with the endpoints
in patients with ToF and aortic coarctation, and a less strong
association in patients with aortic stenosis, when compared
with estimates from the entire cohort (Supplemental
Figure S1).
Hs-TnT change during the first year
In patients with stable, undetectable hs-TnT levels during
the first year of follow-up, the event-free survival was signifi-
cantly higher, compared with patients who had changing
hs-TnT levels during the first year (Fig. 3). Of note, inter-
pretation of absolute decreases or increases of hs-TnT in this
analysis should be done with caution because of regression
towards the mean.20Discussion
Clinically stable patients with ACHD who had an adverse
cardiac event within 6 years after inclusion had systematically
higher hs-TnT at baseline and during follow-up, and values
tended to increase before the occurrence of an adverse cardiac
event. This seems to reveal a process of ongoing and enhanced
cardiomyocyte loss in mostly asymptomatic patients with
ACHD. Particularly undetectable, stable hs-TnT levels (<3
ng/L) were present in patients with a more favourable prog-
nosis. Although repeated hs-TnT yielded prognostic value foradverse cardiac events independently of a single baseline
NT-proBNP measurement, repeatedly measured hs-TnT did
not yield prognostic value independent of repeated NT-pro-
BNP measurements.Value of hs-TnT as prognostic biomarker
The prognostic value of hs-TnT was described for the first
time in this same cohort of patients with ACHD.5,12 Mean-
while, several other studies have confirmed the prognostic
relevance of hs-TnT in some ACHD diagnoses.11,21-23
Rybicka et al.11 investigated hs-TnT levels in 131 stable pa-
tients with ACHD and found an association with systemic
ventricular dysfunction. In adults with congenitally corrected
transposition of the great arteries, hs-TnT was associated with
systemic right ventricular function and was even superior to
NT-proBNP in detecting systemic ventricular dysfunction.22
Moreover, hs-TnT was predictive of adverse cardiac events
in these patients.21 These studies indicate that hs-TnT release
and its prognostic value are not restricted to patients with
systemic left ventricles, or certain types of ACHD. Subgroup
analysis in our study further supports this; baseline hs-TnT
yields prognostic value in adults with ToF, aortic coarcta-
tion, or aortic stenosis. Especially in ToF, the association with
death or HF for both a single and repeated hs-TnT mea-
surements was strong.
To the best of our knowledge, this is the first study that
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Figure 2. Average evolution of hs-TnT in patients with and without the secondary endpoint. Measurements taken after the endpoint were discarded.
Time point zero is denoted as the time of study inclusion (A) or as the time when the event took place (B). HF, heart failure; hs-TnT, high-sensitivity
troponin T.
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hs-TnT has more extensively been investigated in patients
with chronic HF.24 The relative change between 2 hs-TnT
measurements within a 4-month time period was associated
with the risk of adverse cardiovascular events in patients with
chronic HF.14 In our study, the absolute change in hs-TnT in
the first year was not associated with outcomes. This is most
likely due to regression towards the mean; measured values of
a random variable fluctuate around a true mean, and extreme
values therefore tend to regress towards the mean, becoming
less extreme.20 The median hs-TnT level was highest in pa-
tients with a decrease in hs-TnT in the first year, supporting
the phenomena of regression towards the mean and subse-
quently the lack of prognostic value found for the absolute hs-
TnT change. Joint modelling, as used in this study, solves this
problem by adjusting for the within-subject variation.18
Temporal hs-TnT patterns investigated in chronic HF using
joint modelling showed that repeated hs-TnT was associated
with adverse cardiovascular events, but not when adjusted for
NT-proBNP and C-reactive protein trajectories.25 Results of
our study are in line with results found in patients with
chronic HF,14,25 suggesting that the role of hs-TnT in the
pathophysiology of HF in patients with chronic HF and those
with ACHD may be quite similar.
Understanding troponin T release in ACHD
The hs-TnT increase over time found in this study may
indicate the existence of a continuous slow troponin T releasefrom the myocardium, which might reflect ongoing subclin-
ical loss of cardiomyocytes. If we assume that the loss of
cardiomyocytes is the result of increased wall stress due to HF
progression, the hs-TnT increase will be preceded by an in-
crease in NT-proBNP, as NT-proBNP is secreted in response
to increased cardiac wall stress.9 This could explain the
prognostic value of serial NT-proBNP independent of serial
hs-TnT and not vice versa. In patients with low baseline NT-
proBNP, a steeper hs-TnT increase was observed than in
patients with elevated NT-proBNP. However, no indepen-
dent value for hs-TnT was found, supporting the hypothesis
that an increase in hs-TnT is preceded by an increasing
NT-proBNP.
Besides myocardial cell death, other mechanisms including
myocardial and subendocardial ischemia, inflammation, and
infiltrative processes may contribute to release of troponin
T.13 This could explain why hs-TnT showed an association
with any adverse cardiac event and not only HF. Contrarily,
the absence of troponin T release, reflected by patients with
undetectable hs-TnT levels, was associated with a low risk of
adverse cardiac events. These patients were also characterized
by more favourable baseline clinical characteristics. The
absence of troponin T release therefore seems to exclude
processes provoking cardiac deterioration and may be helpful
to detect low-risk patients.
Hs-TnT levels also increase with a worsening renal func-
tion, by diminished renal clearance of troponin T.26,27
Although patients with severe renal dysfunction were not
included in this study, hs-TnT levels could have been
Table 4. Associations between repeated hs-TnT levels and endpoints
Primary endpoint Secondary endpoint
HR (95% CI) P-value HR (95%CI) P-value
Repeated hs-TnT (unadjusted) 1.62 (1.44-1.81) < 0.001 2.58 (2.13-3.14) < 0.001
Adjusted for baseline characteristics* 1.26 (1.09-1.47) 0.004 1.73 (1.31-2.28) < 0.001
Adjusted for baseline NT-proBNP 1.21 (1.06-1.38) 0.002 1.34 (1.05-1.72) 0.016
Adjusted for baseline characteristics
and baseline NT-proBNP
1.07 (0.90-1.26) 0.436 1.31 (0.96-1.80) 0.086
Repeated hs-TnT and NT-proBNP
Repeated hs-TnT 1.12 (0.98-1.30) 0.102 1.19 (0.89-1.58) 0.262
Repeated NT-proBNP 1.53 (1.38-1.70) < 0.001 2.42 (1.93-3.04) < 0.001
Repeated hs-TnT and eGFR
Repeated hs-TnT 1.50 (1.32-1.70) < 0.001 2.49 (1.95-3.16) < 0.001
Repeated eGFR 0.59 (0.39-0.94) 0.028 0.69 (0.39-1.38) 0.240
HRs are expressed per 2-fold higher biomarker level, at any point in time during follow-up.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro B-type
natriuretic peptide.
* Age, sex, congenital diagnosis, NYHA, any cardiac medication, loss of sinus rhythm, systemic ventricular function, eGFR.
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Nevertheless, serial hs-TnT measurements remained predic-
tive of both endpoints, independent of serial eGFR. There-
fore, it is likely that the hs-TnT increase is the result of
cardiomyocyte loss rather than the effect of a decreased renal
clearance of hs-TnT.Clinical perspective
A single hs-TnT measurement can be used as prognos-
ticator in patients with ACHD besides NT-proBNP to
further discriminate between high- and low-risk patients.5
In addition, this study showed that serially measuring
hs-TnT can enhance precision in estimating prognosis inFigure 3. Event-free and heart failure-free survival according to the change
comparison of survival in stable patients vs the other groups. Of note, a subs
measurement at baseline and at 1 year could be included (other hs-TnT me
from year 1 onwards (patients had to be alive at t ¼ 1 year). hs-TnT, high-saddition to a single measurement. Particularly, stable, un-
detectable hs-TnT levels seem to identify low-risk patients
whom can be reassured. Nonetheless, repeated hs-TnT may
not be the biomarker of first choice; repeatedly measuring
NT-proBNP for monitoring and risk assessment in clini-
cally stable patients with ACHD over time seems more
valuable. However, clinicians should be aware of the
biological and analytical variability of biomarkers28 and the
subsequent effect of regression towards the mean, when
interpreting repeatedly measured biomarkers.
As previously described, elevated levels of hs-TnT are not
uncommon in asymptomatic patients with ACHD.12 With
the ageing ACHD population,3 coronary artery disease is
likely to become more prevalent and a bigger threat to thesein hs-TnT in the first year (D year 1-year 0). Log-rank test represents
et of the data was used in this analysis; only patients with both hs-TnT
asurements were discarded), and the time to event was recalculated
ensitivity troponin T.
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Volume - 2020patients. In the management of coronary artery disease in
patients with ACHD, it should be taken into account that hs-
TnT levels are higher in these patients and increase over time.
Limitations
Hs-TnT was measured in thawed serum samples, which
had been stored by 80C. Hs-TnT is known to be stable up
to at least 1 year at 80C,29 whereas samples in our study
had been stored >1 year. However, we did not find a corre-
lation between storage time within each follow-up moment
and hs-TnT levels. Therefore, it is unlikely that levels of hs-
TnT have been affected by storage time.
We measured hs-TnT annually, and because of the rela-
tively long time interval between 2 measurements, the time in
between biomarker measurement and the onset of a cardio-
vascular event differs in each case. The last measurement taken
before the event may therefore differ from the actual
biomarker level prior or at the moment of the actual event.
This may also have prevented us to notice more pronounced
increases in hs-TnT in anticipation to events. More frequent
blood sampling than performed in our study would be needed
to more precisely investigate this.
This study consisted of patients with ACHD with different
underlying congenital heart defects. Unfortunately, we were
restricted by the sample size to perform subgroup analyses for
each diagnosis.Conclusions
In clinically stable patients with ACHD, hs-TnT levels
modestly increased over time, indicating loss of car-
diomyocytes that might reflect subclinical as well as clinical
progression of HF in these patients. Particularly, stable, un-
detectable hs-TnT levels may identify low-risk patients.
However, the additive prognostic value of serial hs-TnT
measurements beyond serial NT-proBNP measurements
seems limited. Whether hs-TnT could aid guidance of follow-
up strategies in specific ACHD diagnoses such as Fontan will
require greater sample sizes and needs to be examined in
future research.Funding Sources
Roche diagnostics provided high-sensitive troponin T as-
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